N. Kuila

EVI1, BAALC and AME: prevalence of the secondary mutations in chronic and accelerated phases of chronic myeloid leukemia patients from eastern India.

S. Chakraborty, G. Biswas, M. Kumari, 2009, Leukemia research.

Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naïve patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India

S. Chakraborty, G. Biswas, N. Dash, 2009, Leukemia & lymphoma.

EVI1 targets ΔNp63 and upregulates the cyclin dependent kinase inhibitor p21 independent of p53 to delay cell cycle progression and cell proliferation in colon cancer cells.

Aditya K Panda, S. Chakraborty, Alok Das Mohapatra, 2013, The international journal of biochemistry & cell biology.

Dual transcripts of BCR-ABL & different polymorphisms in chronic myeloid leukaemia patients

S. Chakraborty, S. Nandagopalan, N. Kuila, 2016, The Indian journal of medical research.

EVI1 up-regulates the stress responsive gene SIRT1 which triggers deacetylation and degradation of EVI1.

Sneha Singh, A. Pradhan, S. Chakraborty, 2011, Biochimica et biophysica acta.

Ecotropic viral integration site I regulates alpha1, 6-fucosyl transferase expression and blocks erythropoiesis in chronic myeloid leukemia

S. Chakraborty, G. Biswas, N. Kuila, 2017, Leukemia & lymphoma.